>
Switch to:

Orgenesis Total Current Assets

: $25.76 Mil (As of Dec. 2021)
View and export this data going back to 2010. Start your Free Trial

Total current assets includes Cash And Cash Equivalents, Accounts Receivable, Total Inventories, and Other Current Assets. Orgenesis's total current assets for the quarter that ended in Dec. 2021 was $25.76 Mil.

Orgenesis Total Current Assets Historical Data

The historical data trend for Orgenesis's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21
Total Current Assets
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.30 30.30 78.35 50.08 25.76

Orgenesis Quarterly Data
Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Total Current Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.08 54.71 47.85 36.34 25.76

Orgenesis Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Orgenesis's Total Current Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Assets=Cash And Cash Equivalents+Accounts Receivable+Total Inventories+Other Current Assets
=5.473+15.245+0.118+1.689
=22.53

Orgenesis's Total Current Assets for the quarter that ended in Dec. 2021 is calculated as

Total Current Assets=Cash And Cash Equivalents+Accounts Receivable+Total Inventories+Other Current Assets
=5.473+15.245+0.118+1.689
=22.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Orgenesis  (NAS:ORGS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Orgenesis's Liquidation Value for the quarter that ended in Dec. 2021 is

Liquidation value
= Cash And Cash Equivalents-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5.473-21.21+0.75 * 15.245+0.5 * 0.118
=-4.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Total Current Assets Related Terms

Thank you for viewing the detailed overview of Orgenesis's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Comparable Companies
NAS:CASI ROCO:6461 NAS:PRTG XKRX:291650 NAS:ENTX TSE:4588 OSTO:ACE NAS:EYEN TSX:ONC XKRX:072520
Traded in Other Exchanges
45O:Germany 45O:Germany
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Website
https://www.orgenesis.com
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

From GuruFocus

Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform

By Marketwired 08-23-2021

Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies

By Marketwired 09-29-2020

Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform

By Marketwired 08-07-2020

Orgenesis and Leidos Collaborate on Potential Treatment for COVID-19

By Marketwired 06-22-2020

Orgenesis and Theracell Joint Venture to Receive up to €32 Million From Greek Government to Accelerate Rollout of POCare Centers and Deployment of OMPULs

By GuruFocusNews 11-29-2021

Orgenesis Achieves Multiple Ranpirnase Development Milestones

By Marketwired 07-06-2021

Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase for the Treatment of External Genital Warts

By Marketwired 08-20-2020

Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy

By Marketwired 03-11-2021

Orgenesis Schedules Fiscal 2020 Year-End Business Update Conference Call

By Marketwired 03-04-2021

Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea

By Marketwired 03-08-2021

Other Sources

$ORGS - Orgenesis: A Mispriced Visionary In Cell And Gene Therapy Manufacturing. Orgenesis A Mispriced Biotech Visionary

By Seekingalpha 2021-05-17

$ORGS - Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2021-11-06

$ORGS - Orgenesis: A Cell And Gene Therapy Disruptor With A Nice Risk Reward Profile. Orgenesis Cell And Gene Therapy Disruptor Nice Risk Reward Profile

By Seekingalpha 2021-01-28

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)